A new study into the online conversations of healthcare professionals discussing prostate cancer has revealed a strong focus on emerging therapies, the latest clinical trials, AI-driven diagnostics ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

The firm submitted data from a Phase III study showing the combination improved outcomes compared to Opdivo and chemo alone.

Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

The application was based on results from the three-arm Phase 3 CheckMate -8HW study.

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification.

Patients with advanced melanoma that had spread to the brain were previously expected to survive for only 16 weeks.

According to Laurence Albiges, MD, PhD, treatment of RCC with cabozantinib, nivolumab, and ipilimumab can cause potentially ...

A groundbreaking Australian clinical trial has shown that a majority of melanoma patients whose cancer has spread to the ...

There are currently 82,000 incident cases of RCC annually in the United States (account for 3–5% of cancers), with 15,000 deaths annually in the United States. The overall 5-year mortality risk is ~30 ...

A combination immunotherapy may help cure a majority of patients with melanoma -- a deadly skin cancer -- that has spread to ...

Liver Cancer Therapeutics Market Growth is Driven by Advancements in Precision Medicine, Immunotherapy and Growing Global Incidence.Pune, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Liver Cancer Therapeutics ...